Clinical trials: Recurrent Glioblastoma Multiforme(GBM)
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Glioblastoma, High Grade Glioma
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or…
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Trial name
- PNOC020 (NCT04573140)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida
Glioblastoma
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
The goal of this clinical research study is to learn if cilengitide given in combination with bevacizumab can help to control glioblastoma. The safety of this drug combination will also be studied.
- Trial name
- NCT01782976
- Testing
- Cilengitide, Bevacizumab, Questionnaire
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months).
- Trial name
- HUTMZ (NCT03463733)
- Testing
- Hydroxyurea, Temozolomide
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- M.E. van Linde
Brain and Central Nervous System Tumors
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003564
- Testing
- Isotretinoin, Procarbazine Hydrochloride
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Adult Glioblastoma Multiforme
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00895180
- Testing
- olaratumab, ramucirumab
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Glioblastoma Multiforme
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients…
- Trial name
- NCT00306618
- Testing
- Panzem Nanocrystal Colloidal Dispersion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM).
- Trial name
- NCT04421378
- Testing
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
- Where
- 18 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Karyopharm Therapeutics Inc
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Malignant
Niraparib and Temozolomide in Patients Glioblastoma
The study evaluates safety, tolerability, pharmacokinetics at recommended phase II dose (RP2D) and preliminary antitumor activity of Niraparib + dd-TMZ "one week on, one week off" in patients affected by recurrent GBM IDH…
- Trial name
- ONC-2022-001 (NCT06258018)
- Testing
- Temodal, Niraparib
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Armando Santoro, MD
Glioblastoma, Recurrent Disease
Pilot Trial for Treatment of Recurrent Glioblastoma
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their…
- Conditions
- Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
- Trial name
- NCT05432518
- Testing
- Afatinib, Dasatinib, Palbociclib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers.
- Trial name
- NCT00376818
- Testing
- exercise intervention, educational intervention, physiologic testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Glioma Tumor Recurrence, Radiation Necrosis
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the…
- Conditions
- Glioma Tumor Recurrence, Radiation Necrosis, Primary Brain Tumor
- Trial name
- NCT00285324
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma, Glioblastoma Multiforme
Treatment of Recurrent GBM With APG-157 Via Expanded Access
This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.
- Trial name
- NCT05551013
- Testing
- APG-157
- Sponsor
- Aveta Biomics, Inc.
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Recurrent Glioblastoma, CD147 Positive
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
- Trial name
- NCT04045847
- Testing
- CD147-CART
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital